Implication of Circulating Extracellular Vesicles-Bound Amyloid-β42 Oligomers in the Progression of Alzheimer's Disease

被引:2
|
作者
Ben Khedher, Mohamed Raafet [1 ,2 ,3 ]
Haddad, Mohamed [1 ,2 ]
Fulop, Tamas [4 ]
Laurin, Danielle [2 ,5 ,6 ]
Ramassamy, Charles [1 ,2 ]
机构
[1] INRS, Ctr Armand Frappier Sante Biotechnol, Laval, PQ, Canada
[2] Inst Nutr & Funct Foods, Quebec City, PQ, Canada
[3] Univ Jendouba, Higher Inst Biotechnol Beja, Beja, Tunisia
[4] Univ Sherbrooke, Res Ctr Aging, Div Geriatr, Dept Med, Sherbrooke, PQ, Canada
[5] Univ Laval, CHU Quebec, VI TAM Ctr Rech Sante Durable, Ctr Excellence Vieillissement Quebec,Res Ctr, Quebec City, PQ, Canada
[6] Laval Univ, Fac Pharm, Quebec City, PQ, Canada
关键词
Alzheimer's disease; amyloid-beta; apolipoprotein J; extracellular vesicles; BLOOD-BRAIN-BARRIER; MILD COGNITIVE IMPAIRMENT; AMYLOID-BETA; EXOSOMES; RECEPTOR; HAPTOGLOBIN; MICROGLIA; PATHWAY; TAU;
D O I
10.3233/JAD-230823
中图分类号
Q189 [神经科学];
学科分类号
071006 ;
摘要
Background: The perplex interrelation between circulating extracellular vesicles (cEVs) and amyloid-beta (A beta) deposits in the context of Alzheimer's disease (AD) is poorly understood. Objective: This study aims to 1) analyze the possible cross-linkage of the neurotoxic amyloid-beta oligomers (oA beta) to the human cEVs, 2) identify cEVs corona proteins associated with oA beta binding, and 3) analyze the distribution and expression of targeted cEVs proteins in preclinical participants converted to AD 5 years later (Pre-AD). Methods: cEVs were isolated from 15 Pre-AD participants and 15 healthy controls selected from the Canadian Study of Health and Aging. Biochemical, clinical, lipid, and inflammatory profiles were measured. oA beta and cEVs interaction was determined by nanoparticle tracking analysis and proteinase K digestion. cEVs bound proteins were determined by ELISA. Results: oA beta were trapped by cEVs and were topologically bound to their external surface. We identified surface-exposed proteins functionally able to conjugate oA beta including apolipoprotein J (apoJ), apoE and RAGE, with apoJ being 30- to 130-fold higher than RAGE and apoE, respectively. The expression of cEVs apoJ was significantly lower in Pre-AD up to 5 years before AD onset. Conclusions: Our findings suggest that cEVs might participate in oA beta clearance and that early dysregulation of cEVs could increase the risk of conversion to AD.
引用
收藏
页码:813 / 825
页数:13
相关论文
共 50 条
  • [41] Plexin-A4 mediates amyloid-β-induced tau pathology in Alzheimer's disease animal model
    Chung, Sunwoo
    Yang, Jinhee
    Kim, Haeng Jun
    Hwang, Eun Mi
    Lee, Wonik
    Suh, Kyujin
    Choi, Hayoung
    Mook-Jung, Inhee
    PROGRESS IN NEUROBIOLOGY, 2021, 203
  • [42] Synaptic Retrogenesis and Amyloid-β in Alzheimer's Disease
    Wasling, Pontus
    Daborg, Jonny
    Riebe, Ilse
    Andersson, My
    Portelius, Erik
    Blennow, Kaj
    Hanse, Eric
    Zetterberg, Henrik
    JOURNAL OF ALZHEIMERS DISEASE, 2009, 16 (01) : 1 - 14
  • [43] Alzheimer's Amyloid-β Oligomers Rescue Cellular Prion Protein Induced Tau Reduction via the Fyn Pathway
    Chen, Rong-Jie
    Chang, Wei-Wei
    Lin, Yu-Chun
    Cheng, Pei-Lin
    Chen, Yun-Ru
    ACS CHEMICAL NEUROSCIENCE, 2013, 4 (09): : 1287 - 1296
  • [44] Distinct spatiotemporal accumulation of N-truncated and full-length amyloid-β42 in Alzheimer's disease
    Shinohara, Mitsuru
    Koga, Shunsuke
    Konno, Takuya
    Nix, Jeremy
    Shinohara, Motoko
    Aoki, Naoya
    Das, Pritam
    Parisi, Joseph E.
    Petersen, Ronald C.
    Rosenberry, Terrone L.
    Dickson, Dennis W.
    Bu, Guojun
    BRAIN, 2017, 140 : 3301 - 3316
  • [45] Extracellular Vesicles from Mesenchymal Stem Cells Exert Pleiotropic Effects on Amyloid-β, Inflammation, and Regeneration: A Spark of Hope for Alzheimer's Disease from Tiny Structures?
    Elia, Chiara A.
    Losurdo, Morris
    Malosio, Maria L.
    Coco, Silvia
    BIOESSAYS, 2019, 41 (04)
  • [46] Comparing Symmetric Dimethylarginine and Amyloid-β42 as Predictors of Alzheimer's Disease Development
    Goodman, Max J.
    Li, Xin Ran
    Livschitz, Jennifer
    Huang, Chiang-Ching
    Bendlin, Barbara B.
    Granadillo, Elias D.
    JOURNAL OF ALZHEIMERS DISEASE REPORTS, 2023, 7 (01) : 1427 - 1444
  • [47] Plasma amyloid-β oligomers level is a biomarker for Alzheimer's disease diagnosis
    Zhou, L.
    Chan, K. H.
    Chu, L. W.
    Kwan, J. S. C.
    Song, Y. Q.
    Chen, L. H.
    Ho, P. W. L.
    Cheng, O. Y.
    Ho, J. W. M.
    Lam, K. S. L.
    BIOCHEMICAL AND BIOPHYSICAL RESEARCH COMMUNICATIONS, 2012, 423 (04) : 697 - 702
  • [48] Cellular prion protein as a receptor for amyloid-β oligomers in Alzheimer's disease
    Salazar, Santiago V.
    Strittmatter, Stephen M.
    BIOCHEMICAL AND BIOPHYSICAL RESEARCH COMMUNICATIONS, 2017, 483 (04) : 1143 - 1147
  • [49] Amyloid-β, tau, and the cholinergic system in Alzheimer's disease: seeking direction in a tangle of clues
    Majdi, Alireza
    Sadigh-Eteghad, Saeed
    Aghsan, Sepideh Rahigh
    Farajdokht, Fereshteh
    Vatandoust, Seyed Mehdi
    Namvaran, Ali
    Mahmoudi, Javad
    REVIEWS IN THE NEUROSCIENCES, 2020, 31 (04) : 391 - 413
  • [50] Cerebrospinal Fluid Aβ42/40 Corresponds Better than Aβ42 to Amyloid PET in Alzheimer's Disease
    Lewczuk, Piotr
    Matzen, Anja
    Blennow, Kaj
    Parnetti, Lucilla
    Molinuevo, Jose Luis
    Eusebi, Paolo
    Kornhuber, Johannes
    Morris, John C.
    Fagan, Anne M.
    JOURNAL OF ALZHEIMERS DISEASE, 2017, 55 (02) : 813 - 822